Pharmafile Logo
Pharmafocus logo
Advanced Search
merckwindow_web

NICE recommends MSD’s Prevymis for CMV prevention following allogeneic haematopoietic stem cell transplant

May 31, 2019
Medical Communications, Sales and Marketing MSD, NICE, Prevymis, UK, cmv, cytomegalovirus, pharma

MSD has revealed that its non-nucleoside CMV inhibitor Prevymis (letermovir) has secured recommendation from NICE, meaning it will now be …

News
cannabis-2152604_960_720

Synthetic, non-intoxicating CBD analogue treats seizures in rats

May 31, 2019
Medical Communications CBD, H2CBD, cannabidiol, medicinal cannabis, pharma

A synthetic, non-intoxicating cannabidiol (CBD)-analogue is effective at treating seizures in rats, according to researchers at the University of California, …

News
novartis_window

Investigational Novartis therapy smashes primary and secondary endpoints in uncontrolled asthma

May 30, 2019
Research and Development Novartis, QVM149, asthma, pharma

Novartis has announced the first findings on the efficacy of its investigational asthma therapy QVM149 in the treatment of inadequately …

News
mercier

Long term BMS exec Johanna Mercier joins Gilead as new Chief Commercial Officer

May 30, 2019
Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, Gilead, cco, commercial, pharma

Gilead Sciences have said Bristol-Myers Squibb exec Johanna Mercier will be the firm’s new Chief Commercial Officer. In her new …

News
novo_flag

Novo Holdings invests £53.5 million into Oxford Biomedica

May 30, 2019
Business Services, Sales and Marketing Novo Holdings, Novo Nordisk, Oxford BioMedica, Shares, cell and gene therapy, lentivirus

Novo Holdings has agreed to buy 10.1% of shares in British firm Oxford Biomedica for £53.5 million. Novo will buy …

News
janssen_latest_logo_on_sign

Janssen presents strong Phase 3 showing for Darzalex in multiple myeloma subgroup

May 30, 2019
Research and Development Janssen, darzalex, pharma

Janssen has lifted the curtain on new Phase 3 data for Darzalex (daratumumab) in combination with lenalidomide and dexamethasone (Rd), …

News

Oklahoma prosecutors say J&J used ‘brainwashing campaign’ to boost opioid sales

May 30, 2019
Research and Development J&J, JJ, opioid crisis, opioids, pharma, public health

Oklahoma state prosecutors have accused Johnson & Johnson of engaging in a “cynical, deceitful, multibillion-dollar brainwashing campaign” to boost sales …

News
920x920

Pharma firms paid Italian doctor to promote opioid drugs

May 29, 2019
Research and Development Italy, Mundipharma, Purdue, opioids, pharma

Opioid drugmakers paid an Italian pain doctor to promote opioid painkillers as a treatment for chronic pain, Italian prosecutors say. …

News
celgene_building

FDA first as agency expands label on Celgene’s Revlimid in previously treated follicular or marginal zone lymphoma

May 29, 2019
Research and Development, Sales and Marketing Cancer, Celgene, FDA, Revlimid, lymphoma, pharma

Celgene has revealed that the FDA has expanded its authorised indications of Revlimid (lenalidomide) to include combination with a rituximab …

News
image_credit_united_states_mission_geneva

UK government refuses to sign up to WHO pricing transparency resolution

May 29, 2019
Research and Development WHA, WHO, access, health UK, pharma, pricing

The UK government has refused to sign up to a global resolution on transparency in drug pricing which urges governments …

News

FDA approves Theranica’s smartphone-controlled electroceutical device for migraine

May 29, 2019
Research and Development FDA, Nerivio Migra, Theranica, migraine, pharma

Biomedical tech company Theranica has secured FDA approval for Nerivio Migra, its wearable, smartphone-controlled electroceutical device, for the acute treatment …

News
citylabs-banner

Manchester emerges as genomics research hub

May 29, 2019
Research and Development Diagnostics, Manchester, UK, genomics, pharma

­­Manchester, UK is emerging as a major hub for genomics research, according to a new firm set up in collaboration …

News
katy_baker

Living with Scimitar syndrome

May 28, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Scimitar syndrome, patient experience, pharma

Katy Baker has lived her entire life with the rare congenital heart defect Scimitar syndrome. She reflects on the system …

Feature

Pfizer’s Lyrica fails at Phase 3 in treating primary generalised tonic-clonic (PGTC) seizures

May 28, 2019
Manufacturing and Production, Research and Development, Sales and Marketing Lyrica, Pfizer, epilepsy, pharma, trial failure

Pfizer has unveiled new Phase 3 data on the effectiveness of Lyrica (pregabalin) in the adjunctive treatment of primary generalised …

News
5204602349_c87b204860_z

FDA delays Newron Pharmaceuticals’ trial into schizophrenia drug evenamide

May 28, 2019
Manufacturing and Production Newron Pharma, evenamide, pharma, schizophrenia

Newron Pharmaceuticals has halted a clinical trial of its schizophrenia drug evenamide after the FDA raised concerns about reports of …

News
industry-smog-factory-environment-pollution-smoke-2043666

Pharma sector is a bigger polluter than the automotive industry

May 28, 2019
Manufacturing and Production CO2, Green, eco-firendly, emissions, pharma, pollution

The pharmaceutical industry is a bigger polluter than the automotive sector, according to a study from researchers at McMaster University. …

News
novartis_side_building

FDA approves first therapy PIK3CA-mutated HR+/HER2- advanced breast cancer

May 28, 2019
Manufacturing and Production, Sales and Marketing Cancer, FDA, Novartis, Piqray, breast cancer, fulvestrant, pharma

Novartis’ Piqray (alpelisib) has secured approval from the FDA in combination with AstraZeneca’s Faslodex (fulvestrant) for the treatment of hormone …

News
novartis_window

Novartis’ $2.15m SMA drug Zolgensma becomes most expensive FDA-approved therapy

May 28, 2019
Manufacturing and Production AveXis, FDA, Zolgensma, access, drugs, pricing, sma

The FDA has approved Novartis subsidiary AveXis’ $2.15 million gene therapy Zolgensma for children with spinal muscular atrophy (SMA). The …

News
5204602349_c87b204860_z

FDA approves new tests for chlamydia and gonorrhoea

May 24, 2019
Medical Communications STIs, chlamydia, gonorrhoea, public health FDA

The FDA has approved two new tests which make it easier to diagnose common STIs. The approval comes after a …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

May 24, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Gilead, J&J, JJ, MSD, Sandoz, pharma, top ten

On the day that UK Prime Minister Theresa May announces her resignation, we look back on the week’s biggest stories …

News
The Gateway to Local Adoption Series

Latest content

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026

PSI appoints David Allen as Country Manager for Canada

January 22, 2026

Qureight appoints Steven Bishop as Chief Medical Officer

January 21, 2026

Pierre Fabre Laboratories and Iktos announce oncology collaboration

January 21, 2026

Qureight appoints Rebecca Simmons as Chief Operating Officer

January 20, 2026